- Home
- BDRX vs ALBT Comparison
BDRX vs ALBT Comparison
Compare BDRX & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ALBT
- Stock Information
- Founded
- BDRX 2000
- ALBT 2014
- Country
- BDRX United Kingdom
- ALBT United States
- Employees
- BDRX N/A
- ALBT N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDRX Health Care
- ALBT Health Care
- Exchange
- BDRX Nasdaq
- ALBT Nasdaq
- Market Cap
- BDRX 5.8M
- ALBT 5.7M
- IPO Year
- BDRX N/A
- ALBT N/A
- Fundamental
- Price
- BDRX $0.90
- ALBT $2.73
- Analyst Decision
- BDRX
- ALBT
- Analyst Count
- BDRX 0
- ALBT 0
- Target Price
- BDRX N/A
- ALBT N/A
- AVG Volume (30 Days)
- BDRX 3.2M
- ALBT 87.1K
- Earning Date
- BDRX 04-11-2025
- ALBT 08-18-2025
- Dividend Yield
- BDRX N/A
- ALBT N/A
- EPS Growth
- BDRX N/A
- ALBT N/A
- EPS
- BDRX N/A
- ALBT N/A
- Revenue
- BDRX N/A
- ALBT $807,235.00
- Revenue This Year
- BDRX N/A
- ALBT N/A
- Revenue Next Year
- BDRX N/A
- ALBT N/A
- P/E Ratio
- BDRX N/A
- ALBT N/A
- Revenue Growth
- BDRX N/A
- ALBT N/A
- 52 Week Low
- BDRX $0.78
- ALBT $2.11
- 52 Week High
- BDRX $41.50
- ALBT $12.60
- Technical
- Relative Strength Index (RSI)
- BDRX 39.25
- ALBT 54.02
- Support Level
- BDRX $0.85
- ALBT $2.65
- Resistance Level
- BDRX $0.97
- ALBT $3.79
- Average True Range (ATR)
- BDRX 0.11
- ALBT 0.27
- MACD
- BDRX -0.00
- ALBT 0.05
- Stochastic Oscillator
- BDRX 28.24
- ALBT 65.85
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.